Inhibition of the vascular-endothelial growth factor-induced intracellular signaling and mitogenesis of human endothelial cells by epigallocatechin-3 gallate

Eur J Pharmacol. 2004 Jan 12;483(2-3):223-7. doi: 10.1016/j.ejphar.2003.10.029.

Abstract

Galloyl group-containing catechins, such as epigallocatechin-3 gallate, inhibit receptor tyrosine kinase activity of several growth factor receptors. This study investigated the effects of epigallocatechin-3 gallate, as compared to epicatechin, on vascular endothelial growth factor-induced intracellular signaling and mitogenesis of human umbilical endothelial cells. Epigallocatechin-3 gallate concentration-dependently inhibited vascular endothelial growth factor-induced DNA synthesis, cell proliferation, autophosphorylation of vascular endothelial growth factor receptors-1 and -2, phosphorylation of extracellular signal-regulated kinases-1 and -2, and mRNA expression of the early growth response factor-1. In contrast, epicatechin was not effective. Thus, epigallocatechin-3 gallate may be an attractive candidate drug to inhibit tumour angiogenesis.

Publication types

  • Comparative Study
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Catechin / analogs & derivatives*
  • Catechin / pharmacology*
  • Cell Division / drug effects
  • Cell Division / physiology
  • Cells, Cultured
  • Endothelial Cells / cytology
  • Endothelial Cells / drug effects*
  • Endothelial Cells / physiology
  • Growth Inhibitors / pharmacology
  • Humans
  • Mitogens / pharmacology*
  • Second Messenger Systems / drug effects*
  • Second Messenger Systems / physiology
  • Vascular Endothelial Growth Factor A / antagonists & inhibitors
  • Vascular Endothelial Growth Factor A / pharmacology*

Substances

  • Growth Inhibitors
  • Mitogens
  • VEGFA protein, human
  • Vascular Endothelial Growth Factor A
  • Catechin
  • epigallocatechin gallate